Cullinan Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||
| EBT Margin | ||||||||||||||||||||||
| EBIT Margin | ||||||||||||||||||||||
| EBITDA Margin | ||||||||||||||||||||||
| Operating Margin | ||||||||||||||||||||||
| Net Margin | ||||||||||||||||||||||
| FCF Margin | ||||||||||||||||||||||
| Efficiency | ||||||||||||||||||||||
| Assets AverageAssets Avg. | 458.88M | 445.29M | 437.32M | 552.36M | 642.24M | 589.18M | 538.05M | 518.49M | 508.35M | 489.44M | 466.81M | 565.32M | 667.24M | 637.54M | 600.75M | 550.00M | 502.23M | 466.25M | 425.68M | 383.39M | ||
| Asset Utilization RatioAsset Util. | 0.04 | |||||||||||||||||||||
| Dividends & Payouts | ||||||||||||||||||||||
| Dividend Coverage RatioDiv. Cover | -11.06 | -61.69 | ||||||||||||||||||||
| FCF Payout RatioFCF Cover | -0.10 | -0.02 | ||||||||||||||||||||
| Dividend YieldDiv. Yield | 0.38% | 0.07% | ||||||||||||||||||||
| Payout Ratio | -0.09 | -0.02 | ||||||||||||||||||||
| Valuation | ||||||||||||||||||||||
| Price to EarningsP/E | -53.97 | -19.98 | -36.36 | 3.34 | -23.56 | -17.85 | -6.92 | -14.27 | -9.88 | -17.10 | -19.68 | -24.06 | -24.05 | -14.99 | -9.18 | -6.37 | -6.94 | -12.31 | -17.61 | -21.86 | ||
| Price to SalesP/S | ||||||||||||||||||||||
| Price to BookP/B | 2.21 | 1.61 | 1.11 | 0.96 | 1.00 | 0.90 | 0.83 | 0.92 | 0.83 | 0.96 | 1.72 | 1.54 | 1.55 | 1.21 | 0.81 | 0.90 | 0.78 | 1.53 | 2.38 | 3.64 | ||
| Enterprise Value | 309.18M | 393.36M | -85.28M | -286.37M | -322.87M | 15.86M | -256.79M | -381.93M | -481.00M | -29.72M | 300.83M | 346.79M | -80.81M | 313.68M | -86.62M | -13.33M | -211.54M | 245.63M | 244.52M | 581.34M | ||
| EV to EBIT | -16.83 | -11.45 | 2.61 | -1.19 | 10.85 | -0.49 | 4.09 | 10.16 | 10.63 | 0.65 | -7.00 | -6.93 | 1.65 | -5.70 | 1.58 | 0.18 | 3.80 | -4.45 | -4.55 | -10.15 | ||
| EV to EBITDA | -16.83 | -11.45 | 2.61 | -1.19 | 10.85 | -0.49 | 4.09 | 10.16 | 10.63 | 0.65 | -7.00 | -6.93 | 1.65 | -5.70 | 1.58 | 0.18 | 3.80 | -4.45 | -4.55 | -10.15 | ||
| Market Capitalization | 985.43M | 683.43M | 467.59M | 581.98M | 586.43M | 483.15M | 402.49M | 459.83M | 386.98M | 437.15M | 733.84M | 1,009.28M | 973.28M | 712.66M | 444.35M | 444.83M | 350.32M | 623.53M | 873.22M | 1,171.74M | ||
| Price to FCFP/FCF | -93.40 | -45.05 | -21.34 | -22.89 | -10.74 | -18.68 | -7.87 | -14.81 | -11.33 | -24.11 | -19.19 | -27.81 | -28.51 | -19.46 | -10.30 | -7.72 | -9.50 | -16.36 | -18.96 | -30.66 | ||
| EV to FCF | -29.30 | -25.93 | 3.89 | 11.27 | 5.91 | -0.61 | 5.02 | 12.30 | 14.09 | 1.64 | -7.87 | -9.56 | 2.37 | -8.56 | 2.01 | 0.23 | 5.74 | -6.44 | -5.31 | -15.21 | ||
| EV to CFO | -29.30 | -25.93 | 3.89 | 11.27 | 5.94 | -0.63 | 5.04 | 12.32 | 14.09 | 1.64 | -7.87 | -9.56 | 2.37 | -8.56 | 2.01 | 0.23 | 5.74 | -6.45 | -5.31 | -15.21 | ||
| Return Ratios | ||||||||||||||||||||||
| Return on Sales [ROS]ROS | -358.73% | |||||||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -13.92% | -15.67% | -24.28% | 31.47% | 23.23% | 25.53% | 22.38% | -32.62% | -36.75% | -41.42% | -38.51% | -33.91% | -29.14% | -32.45% | -36.44% | -44.97% | -51.43% | -56.39% | -61.55% | -64.71% | ||
| Return on Assets [ROA]ROA | -13.59% | -15.16% | -18.70% | 19.69% | 15.90% | 18.54% | 11.89% | -27.45% | -30.81% | -31.69% | -28.76% | -25.47% | -21.77% | -26.24% | -29.69% | -37.51% | -43.07% | -47.06% | -51.83% | -53.30% |